Protagonist CMO Sells $1.57M in Stock After Option Exercise as Icotyde Approval Spurs Analyst Upgrades
Arturo Molina, M.D., the chief medical officer of Protagonist Therapeutics (PTGX), sold 15,000 shares of common stock on March 26, 2026, generating about $1.57 million. Molina also exercised options to acquire 15,000 shares at $8.04. The trades come as Protagonist shares have climbed sharply following FDA approval of Icotyde (icotrokinra), promptin…